Explore ViiV Healthcare

amfAR TREAT Asia

Photo courtesy of Kevin Tachman/TREAT Asia

What we do

Annette Sohn2

Our programme supports interventions and activities that include:

  • Monitoring for the emergence of advanced HIV drug-resistance in children who have failed first-line or are already on second-line ART to identify the antiretrovirals needed to optimise regimen sequencing – something that’s not been done in a structured way in other resource-limited settings.
  • Applying computer-assisted survey technology and utilising mobile phone text messaging to assess and encourage adherence in adolescents growing up with HIV.
  • Conducting pharmacokinetic studies of novel and second-line ARVs to evaluate dosing recommendations for Asian infants and children.
  • Studying ART toxicity and outcomes, including the use of protease inhibitors and switch practices among adolescents.
  • Examining reproductive health issues by studying use of oral contraceptives and drug interactions with ART, in order to inform a model of reproductive health services for adolescent females living with HIV in Asia. One hundred sexually active HIV-positive adolescent females and young women between 12 and 24 years of age will be enrolled in this project.
  • Annette Sohn3 Studying prevention of bone demineralisation in children and adolescents in Asia. This 48-week study will be conducted at sites in Thailand and Indonesia among almost 250 adolescents.
  • Educating paediatricians on treatment failure, drug resistance, lipodystrophy management and optimisation of ART sequencing for children.
  • Research-capacity building and training for paediatric HIV providers.
  • Advocating for safe and effective HIV care and treatment for children in the region and across the globe.

Key Facts

Project: A multi-year partnership designed to optimise the quality of healthcare for infants, children and adolescents living with HIV across Asia.

Run by: TREAT Asia/amfAR

Region: Asia-Pacific

Population: Infants, children and adolescents living with HIV

Challenges: High first-line antiretroviral therapy (ART) failure rates among children; Limited availability of ART regimens that can be dosed and delivered to newborns and young children, and that are safe to use during growth and development; Poor access to once-daily fixed-dose combination medicines and third-line options for adolescents; Gaps in research capacity and higher-level training for paediatric HIV providers.

Activities: Conducting integrated and innovative programmes in research, provider education and global advocacy, with a focus on treatment failure, the emergence of drug-resistance and optimising antiretroviral sequencing for children living with HIV, among other important considerations for paediatric populations in the region and across the globe.